4.7 Article

Targeting SOST using a small-molecule compound retards breast cancer bone metastasis

Journal

MOLECULAR CANCER
Volume 21, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12943-022-01697-4

Keywords

SOST; Bone metastasis; Breast cancer; Small-molecule compound

Funding

  1. National Natural Science Foundation of China [81872159, 81902607]
  2. 345 Talent Project of Shengjing Hospital of China Medical University

Ask authors/readers for more resources

The study found an association between SOST expression and breast cancer bone metastases and poor survival rates; SOST silencing significantly reduced the bone metastatic capacity of breast cancer cells, while the interaction of SOST with STAT3 enhanced TGF-beta/KRAS signaling, leading to increased tumor growth and bone metastasis.
Background: Breast cancer metastasis to the bone can be exacerbated by osteoporosis, is associated with poor long-term survival, and has limited therapeutic options. Sclerostin (SOST) is an endogenous inhibitor of bone formation, and an attractive target for treatment of osteoporosis. However, it is unclear whether SOST can be used as a therapeutic target for bone metastases of breast cancer, and whether small molecule compounds that target SOST in breast cancer cells can inhibit breast cancer bone metastasis. Methods: SOST expression in 442 breast cancer tissues was characterized by immunohistochemistry and statistically analyzed for the association with breast cancer bone metastases. Bone metastatic breast cancer SCP2 cells were induced for SOST silencing or overexpression and their bone metastatic behaviors were tested in vitro and in vivo. To identify potential therapeutics, we screened inhibitors of the interaction of SOST with STAT3 from a small chemical molecule library and tested the inhibitory effects of one inhibitor on breast cancer growth and bone metastasis in vitro and in vivo. Results: We found that up-regulated SOST expression was associated with breast cancer bone metastases and worse survival of breast cancer patients. SOST silencing significantly reduced the bone metastatic capacity of SCP2 cells. SOST interacted with STAT3 to enhance the TGF-beta/KRAS signaling, increasing both tumor growth and bone metastasis. Treatment with one lead candidate, S6, significantly inhibited the growth of breast-cancer organoids and bone metastasis in mice. Conclusions: Our findings highlight a new class of potential therapeutics for treatment of bone metastasis in breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available